

SCIENTIFIC PROGRAMME

# 1<sup>st</sup> B. I. Similar Forum

Regional Immunology Expert Forum

1-2 December 2016, Vienna, Austria

Schloss Schönbrunn Apothekertrakt

Entrance Meidlinger Tor | Grünbergerstrasse, 1130 Vienna

**Organiser:** Update Europe – Society for Postgraduate Medical Training,  
Lazarettgasse 19, 1090 Vienna, Austria  
Tel. +43/1/405 57 34, E-mail: [office@update.europe.at](mailto:office@update.europe.at)



Boehringer  
Ingelheim

# SCIENTIFIC PROGRAMME

1 December 2016, Vienna, Austria

09.00 – 09.15 **Welcome & Opening remarks**  
Prof. Josef Smolen, Medical University Vienna, Austria

## I. Update on Immunology Research from the Lab

09.15 – 10.15 **What are the latest immunological insights and how can they advance our understanding of chronic inflammatory diseases?**  
Dr. Thomas Decker, University of Vienna, Austria

10.15 – 10.45 **Coffee break**

10.45 – 11.45 **Biosimilars preclinical and clinical development**  
Dr. Deepak Assudani, Boehringer Ingelheim, Germany

11.45 – 12.00 **Discussion**

12.00 – 13.00 **Business Lunch Buffet**

## II. Clinical Practice: Breakout sessions RA/CD/PsO

The Breakout sessions will run simultaneously

### Breakout session Rheumatoid Arthritis | Moderator: Prof. Josef Smolen


13.00 – 13.45 **Current clinical treatment landscape in RA**  
Prof. Catalin Codreanu, Center for Rheumatic Diseases, Bucharest, Romania

13.45 – 14.30 **Treatment outlook in RA – value of TNF inhibitors in the era of multiple biologics**  
Prof. Jiří Vencovský, Institute of Rheumatology, Prague, Czech Republic

14.30 – 15.15 **Discussion**

15.15 – 15.45 **Coffee break**

15.45 – 16.30 **Specific focus on treatment situation in Eastern Europe**  
Prof. Gyula Poór, Semmelweis University, Budapest, Hungary



# SCIENTIFIC PROGRAMME


1 December 2016, Vienna, Austria

## Breakout session Crohn's Disease | Moderator: Prof. Grazyna Rydzewska

- |               |  |
|---------------|--|
| 13.00 – 13.45 | <b>Current clinical treatment landscape in CD</b><br>Prof. Grazyna Rydzewska, Gastroenterology Clinic in Central Hospital MSW, Warsaw, Poland              |
| 13.45 – 14.30 | <b>Treatment outlook in CD – value of TNF inhibitors in the era of multiple biologics</b><br>Prof. Milan Lukáš, ISCARE I.V.F., a.s. Prague, Czech Republic |
| 14.30 – 15.15 | Discussion   |
| 15.15 – 15.45 | Coffee break   |
| 15.45 – 16.30 | <b>Specific focus on treatment situation in Eastern Europe</b><br>Krisztina Gecse, MD, PhD, Semmelweis University, Budapest, Hungary                       |

## Breakout session "Current clinical treatment landscape in PsO" | Moderator: Prof. Georg Stingl

- |               |  |
|---------------|--|
| 13.00 – 13.45 | <b>Nonbiologic systemic therapies</b><br>Prof. Peter van de Kerkhof, Radboud University Nijmegen Medical Centre, The Netherlands   |
| 13.45 – 14.30 | <b>Psoriasis and more: value of TNF inhibitors in the era of multiple biologics</b><br>Prof. Georg Stingl, Medical University Vienna, Austria  |
| 14.30 – 15.15 | <b>Psoriasis treatment: New developments</b><br>Prof. Alexander Navarini, University of Zurich, Switzerland  |
| 15.15 – 15.45 | Coffee break   |
| 15.45 – 16.30 | <b>Specific focus on treatment situation in Eastern Europe</b><br>Prof. Petr Arenberger, Charles University Third School of Medicine Prague, Czech Republic<br>Prof. Lajos Kemény, University of Szeged, Hungary<br>Prof. Branka Marinovic, University Hospital Center Zagreb, Croatia |



# SCIENTIFIC PROGRAMME

2 December 2016, Vienna, Austria

09.00 – 09.15 **Introduction**

Phillip von Lattorff, Boehringer Ingelheim, Austria

09.15 – 10.00 **Guest lecture “From bone loss to breast cancer prevention”**

Prof. Josef Penninger, IMBA – Institute of Molecular Biotechnology Vienna, Austria

## III. Biosimilars focus on quality

10.00 – 10.30 **Optimization of product quality to meet the demands of a biosimilar product**

Dr. Joey Studts, Boehringer Ingelheim, Germany

10.30 – 11.00 **Regulatory framework for ensuring highest quality standard**

Julie Maréchal, Medicines for Europe, Brussels, Belgium

11.00 – 11.30 **Presentation of the NOR-SWITCH study results**

Guro Løvik Goll, MD, PhD, Diakonhjemmet Hospital, Oslo, Norway

11.30 – 12.00 **Coffee break**

## IV. Patients' and physicians' acceptance of biosimilars

12.00 – 12.30 **Efficacy and safety of biosimilars in the “real world”**

Prof. Clemens Scheinecker, Medical University Vienna, Austria

12.30 – 13.00 **Role of patient advocacy groups**

Tanita Wilhelmer, Österreichische Rheumaliga, Austria

13.00 – 14.00 **Lunch buffet**

## V. Opportunities and challenges to have biosimilars available

14.00 – 14.30 **Key note lecture: Variation across EU in payer policy**

Pieter Dylst, MD, Medicines for Europe, Brussels, Belgium

14.30 – 15.30 **Round table discussion:**

**Can Europe afford universal health care? Access to services between equity and efficiency**

Moderator: Armin Fidler MD, MPH, MSc., MCI Management Center Innsbruck, Austria  
(including Interactive Voting System)

15.30 – 16.00 **Summary & Outlook**

Prof. Josef Smolen